The role nitric oxide (NO) plays in the cardiovascular system is complex and diverse. Even more controversial is the role that the inducible NO synthase enzyme (iNOS) serves in mediating different aspects of cardiovascular pathophysiology. Following arterial injury, NO has been shown to serve many vasoprotective roles, including inhibition of platelet aggregation and adherence to the site of injury, inhibition of leukocyte adherence, inhibition of vascular smooth muscle cell (VSMC) proliferation and migration, and stimulation of endothelial cell (EC) growth. These properties function together to preserve a normal vascular environment following injury. In this review, we discuss what is known about the involvement of iNOS in the vascular injury response. Additionally, we discuss the beneficial role of iNOS gene transfer to the vasculature in preventing the development of neointimal thickening. Lastly, the pathophysiology of transplant vasculopathy is discussed as well as the role of iNOS in this setting.
Introduction
vasculopathy, a process that greatly resembles the arterial injury response, as well as the role of iNOS in this disease Nitric oxide (NO), while outwardly a simple molecule, process will re reviewed. has been shown to play very diverse roles in the physiology and pathophysiology of the cardiovascular system. Since the discovery of the NO pathway in 1987 and the 2. Nitric oxide synthase isoforms and nitric oxide elucidation that NO is intimately involved in the regulation of vasomotor tone, NO has earned the conflicting reputa-NO is synthesized by a family of enzymes called NO tion of being both protective and deleterious to vascular synthases (NOS). The three different isoforms include homeostasis. The loss of endothelial ability to constitutiveendothelial NOS (eNOS), neuronal NOS (nNOS) and ly synthesize and release NO has been suggested to be the inducible NOS (iNOS). These isoforms, while clearly inciting event in atherogenesis [1, 2] . In contrast, however, distinct, share a number of similarities. The enzymatic inducible NO synthase (iNOS) has been detected in reaction involves the 5-electron oxidation of one of the atherosclerotic plaques and the local release of large guanidino nitrogens of L-arginine in the presence of amounts of NO has been linked to the production of molecular oxygen to generate NO and its byproduct, Lharmful oxidative products such as peroxynitrite [3] [4] [5] .
citrulline [6, 7] . They all require the cofactors NADPH, The focus of this review will be limited to iNOS and its FAD, FMN, heme, and tetrahydrobiopterin to catalyze this involvement in the vascular injury response, an area that reaction [6, 7] . In general, eNOS and nNOS are constitumore clearly demonstrates the potential benefits of NO tively expressed enzymes and NO production is regulated 21 production. Additionally, the pathophysiology of transplant predominantly by intracellular Ca fluxes that permit calmodulin binding which activates the enzymes [7] . In contrast, iNOS is transcriptionally regulated and is not normally produced by most cells [7, 8] . Typically, iNOS is injury, there is a marked upregulation of the genes that expressed in response to cellular stress and generates encode for extracellular matrix proteins, such as collagen 100-1000-fold more NO than its constitutive counterparts and elastin. Deposition of the extracellular matrix is a whose roles are involved in physiologic regulation [8, 9] . significant component of the vascular remodeling that NO is a highly diffusible molecule and can reach distant occurs after injury. As an end result of this complex cells quickly [10] . The biologic half-life of NO is on the process intimal thickening occurs at the site of injury, and order of seconds which restricts its actions to the local this encroachment on the lumen may be countered by environment [10] . NO is avidly bound by hemoglobin vascular remodeling which leads to a compensatory inwhich then converts it to the inactive end products, nitrite crease in vessel diameter. and nitrate, another mechanism by which the body prevents systemic toxicity [10] . NO can also interact with superoxide to produce peroxynitrite and other potentially 4. Mechanisms of nitric oxide mediated toxic oxidants that may be involved in tissue injury and vasoprotection organ dysfunction [11] .
4.1. Role of platelet adherence 3. The arterial injury response NO has been shown to be vasoprotective through a variety of different mechanisms (Fig. 1) . One of the initial To fully appreciate the beneficial role iNOS plays in the observations was the capacity of NO to prevent platelet arterial injury response, a brief review of the events that adherence and aggregation [23] . The inhibition of platelet occur following arterial injury is required (for reviews, see adhesion was found to be mediated by cGMP, not cAMP, Refs. [12] [13] [14] [15] [16] [17] [18] ). Injury to the arterial wall, either through by using selective inhibitors of cGMP and cAMP phosphoballoon angioplasty or multiple passes of a balloon cathediesterase [24] . More recently, human platelets have been ter, leads to endothelial denudation and possible rupture of shown to express iNOS and eNOS isoforms [25] . Porcine the internal elastic lamina (IEL) with damage to the platelets upon activation and aggregation express iNOS, underlying smooth muscle cell (SMC) layer. Following potentially leading to a negative feedback loop to further endothelial denudation and exposure of the underlying IEL suppress excessive platelet aggregation [26] . and SMC layer, platelets immediately aggregate and Arterial injury results in the exposure of collagen to adhere to the site of injury. Leukocyte chemotaxis then circulating blood elements causing platelets to aggregate at follows and an array of cytokines and growth factors are the site of injury. Injury also results in the upregulation of secreted which have multiple effects. Basic fibroblast iNOS in vascular smooth muscle cells (VSMC) in the growth factor (bFGF) is responsible for the first wave of arterial wall [27, 28] . In 1996, Yan [28] showed that this smooth muscle cell proliferation following injury [19] .
upregulation of iNOS in vivo not only prevented the Platelet derived growth factor (PDGF) is mainly responadherence of platelets to the injured site but also preserved sible for the migration of SMCs from the media to the blood flow. These investigators injured rat carotid arteries intima [20] , and transforming growth factor-b (TGF-b) with a balloon catheter and exposed vessels to the NOS potently stimulates interstitial collagen gene expression by inhibitor L-NAME. L-NAME resulted in a 3-fold increase 111 human SMC, leading to extracellular matrix deposition in In-labeled platelets to the site of injury and a 24% [21] .
reduction of blood flow. Because the injury resulted in the Activation of SMCs by these growth factors converts endothelial denudation with loss of eNOS, it was conthem from a contractile to a synthetic phenotype (for cluded that the upregulation of iNOS represents a protecreviews, see Refs. [12] [13] [14] [15] [16] [17] [18] ). Smooth muscle proliferation tive mechanism against platelet adherence that compenthen follows as early as 24 h following injury and sates for the loss of the endothelium. continues for at least 2 weeks. In order for the SMCs to migrate from the media to the intima, the extracellular 4.2. Role of nitric oxide inhibition of leukocyte matrix and IEL must undergo some degree of degradation chemotaxis as these act as barriers to migration. Plasminogen activators, proteases that lyse clots and activate matrixLeukocyte accumulation at the site of arterial injury degrading enzymes, and matrix metalloproteinases, which leads to the production of a several growth factors and degrade collagen and elastin, are upregulated following cytokines that stimulate VSMC proliferation and migration. injury. This degradation of the extracellular matrix allows NO has been shown to inhibit this leukocyte chemotatic SMCs to migrate to the intima between 1-3 days followresponse and hence negatively effect the downstream ing injury, where they continue to proliferate for several events. In 1991, Kubes et al. [29] infused cat mesenteric weeks. Concurrently, endothelial regeneration occurs preparations with inhibitors of NO production and obthrough the stimulation of bFGF within 24 h after injury, served single venules by intravital video microscopy. Both and can continue for 6-10 weeks [22] . Lastly, following L-NAME and L-NMMA increased leukocyte adherence more than 15-fold. Additionally, L-NAME induced adhestrated that NO produced from iNOS inhibited the activasion was reversed by L-arginine but not D-arginine, sugtion of NFkB. Thus, iNOS upregulation in the vessel wall gesting that this is a NO-specific event. To specifically can impair both PMN and monocyte accumulation. Deevaluate the role of iNOS in the leukocyte-endothelium monstration that this occurs following vascular injury has interaction, iNOS knock out mice were studied [30] . Using not been reported. Although, since the upregulation of a model of endotoxemia the authors demonstrated that the iNOS following vascular injury is a relatively delayed number of rolling and adherent leukocytes in the creevent (24 h) it is possible that iNOS expression serves to masteric postcapillary venules and liver postsinusoidal resolve inflammation through this mechanism. venules of iNOS-deficient mice were significantly greater compared to the wild-type mice. These results suggest that 4.3. Nitric oxide inhibition of VSMC proliferation NO produced following iNOS upregulation may function as a homeostatic regulator of leukocyte recruitment and
In 1989, Garg et al. [32] demonstrated that NO-generatmay play an important role in vascular inflammation.
ing vasodilators could inhibit rat aortic smooth muscle cell Inducible NOS expression has also been shown to limit (RASMC) proliferation. They administered sodium nitromonocyte adherence to the vessel wall. Peng et al. [31] prusside (SNP), S-nitroso-N-acetylpenicillamine (SNAP), demonstrated that iNOS prevented monocyte adhesion to and isosorbide dinitrite exogenously to RASMC and endothelial cells through the downregulation of VCAM-1 demonstrated a dose-dependent inhibition of RASMC 3 gene transcription by inhibiting nuclear factor-kappa B proliferation assessed by serum-induced [ H]thymidine (NFkB). Using endothelial and RAW cell co-cultures, they incorporation. Several studies following this publication stimulated iNOS production with bacterial LPS and IFNdemonstrated the beneficial effect of delivering excess NO gamma and measured VCAM-1 expression and monocyte to the site of vascular injury to prevent the development of adherence to the endothelial surface. Expression of iNOS intimal hyperplasia in vivo. In 1993, McNamara et al. [33] was associated with decreased VCAM-1 mRNA and administered the nitric oxide precursor L-arginine to rabbits reduced monocyte-endothelial cell interaction. Both effrom 2 days prior to 2 weeks following catheter-induced fects were prevented in the presence of a nonspecific NOS injury to the rabbit thoracic aorta. Animals receiving Linhibitor. Using immunofluorescent studies with antibodies arginine displayed 39% less intimal hyperplasia compared to the RelA (p65) subunit of NFkB, they then demonto control untreated animals. This reduction in intimal hyperplasia was reversed by co-administration of Lsubsequent phosphorylation of the retinoblastoma protein, NAME. In 1995, Marks et al. [34] showed that a single both of which are necessary for cell cycle progression. treatment with a protein adduct of NO that possesses a Most recently, this inhibition of proliferation and upregulaprolonged biologic half-life prevented intimal hyperplasia tion was determined to be independent of the tumor in response to vascular injury. Rabbit femoral arteries were suppressor gene p53 [40] . p53 has long been shown to injured with balloon-catheter denudation and exposed to upregulate p21 transcription and it has been thought that the NO protein adduct for 15 min. The single treatment one way p53 is able to induce cell cycle arrest is thought with the NO protein adduct inhibited the development of its ability to upregulate p21. Since NO has been shown to intimal hyperplasia by 77% compared to the controls at 14 increase the expression of p53 [41] , it was thought that this days. To demonstrate efficacy of NO in preventing the was one mechanism by which NO could lead to inhibition injury response in a model more closely resembling human of VSMC proliferation. We isolated SMCs from p53 knock conditions, Groves et al. [35] showed that 3 weeks of out mice, and found that NO was able to inhibit VSMC treatment with an oral NO donor molsidomine resulted in a proliferation in these p532 / 2 cells and that it was still 32% reduction in intimal thickness following angioplasty associated with the upregulation of p21 by Western blot in porcine carotid arteries. Lee et al. [36] showed that analysis [40] . Hence NO upregulates p21 and inhibits chronic inhalation of NO following balloon-induced arteri-VSMC proliferation independent of p53. al injury in the rat carotid artery resulted in a 43% decrease in the intima / media area ratio at 2 weeks.
Effects of nitric oxide on VSMC migration
The specific role of endogenous iNOS in this injury response was first determined by Hansson et al. in 1994 Just as VSMC proliferation is imperative to the forma- [27] . They found that iNOS mRNA was upregulated in the tion of the neointima, so is migration of the SMCs from medial smooth muscle cells following balloon-induced the media to the neointima. NO has also been shown to endothelial denudation from 1-14 days following injury.
retard this process. In 1995, Dubey et al. [42] showed that In 1996, the same group demonstrated that this upregula-SNP and SNAP could inhibit angiotensin II induced SMC tion of iNOS in vivo following arterial injury also premigration by |60%. RASMC migration was assessed vented adherence of platelets to the injured vasculature and using a modified Boydens chamber. To determine if NO preserved blood flow by administering inhibitors of iNOS produced from iNOS would inhibit this migratory process, [28] . More recently, Yan et al. [37] demonstrated that not they stimulated iNOS expression using IL-1b and showed only did medial SMCs show upregulation of iNOS but that that NO could also inhibit migration of the RASMCs by neointimal cells displayed a greater expression of iNOS by |60%. Sarkar et al. [43] demonstrated that three other both Western blot and Northern blot analysis. Interestingly, donors of NO, namely diethylamine NONO-ate, spermine this upregulation by the neointimal cells was due to more NONOate, and S-nitrosoglutathione, all exhibited concenefficient activation of the iNOS promoter as demonstrated tration-dependent inhibition of both the number of SMCs by transfection studies using a reporter gene under the migrating and the maximal distance migrated following control of the iNOS promoter. However, the neointimal wounding of a confluent culture of RASMCs. This inhibicells were less responsive to the antiproliferative effects of tion was reversible upon removal of the NO donors. NO than the medial smooth muscle cells as measured by Measurements of VSMC protein synthesis and mitochonthe inhibition of cellular proliferation. As with the other drial respiration indicated that inhibition of migration by protective actions of iNOS following vascular injury, the these NO donors was not due to metabolic cytostasis. expression of iNOS possibly functions to resolve the injury response and limit excessive SMC proliferation.
Protective effects of nitric oxide on endothelial cells Much work has gone into determining how NO inhibits VSMC proliferation. One mechanism is through the induc-
In addition to the action of NO on VSMC responses tion of a G0 / G1 cell cycle arrest, preventing cells from following injury, NO has also been shown to effect entering the synthesis phase of the cell cycle and undergoendothelial cell pathophysiology during the injury reing proliferation. Sarkar et al. [38] treated cultured sponse. Some evidence indicates that NO stimulates the RASMCs with SNAP and S-nitrosoglutathione and obgrowth of endothelial cells. One example comes from served a 50% decrease in the cells in the G2 / M and S studies examining angiogenesis, a process that requires the phases of the cell cycle and a corresponding increase in the stimulation of proliferation and migration of endothelial cells in G0 / G1. This cell cycle arrest was reversible upon cells. In 1994, Ziche et al. [44] evaluated the effects of NO withdraw of the NO donors. Ishida et al. [39] in 1997 donors and endogenous NO on the angiogenesis process. demonstrated that as SNAP induced a G0 / G1 cell cycle They monitored the angiogenic response in rabbit corneas arrest that was associated with inhibition of VSMC and found that sodium nitroprusside (SNP) potentiated proliferation. NO also induced a significant upregulation of angiogenesis and this was inhibited by L-NAME. By the cell cycle inhibitor p21. Additionally, they demonexamining coronary endothelial cells in culture, they found strated that NO inhibited the activity of cdk2 and the that NO generating compounds such as SNP, isosorbide dinitrate, and glyceryl trinitrate, produced a dose-depencalcium-independent fashion. Therefore, iNOS may have dent increase in endothelial cell proliferation as measured advantages over eNOS or nNOS which both require post- 3 by [ H]thymidine incorporation. Additionally, migration translational modifications for activity. With these greater assessed using a modified Boydens chamber was also NO producing characteristics one can hypothesize that less potentiated by NO generating agents. Endogenous proadenovirus could be used to effectuate the same results. duction of NO following stimulation of the coronary This is beneficial given the host immune response evoked endothelial cells with substance P also resulted in an with current first and second generation adenoviral vectors. increased proliferative and migratory response in these Using less virus might lead to less of an inflammatory cells, both of which were prevented with pre-treatment response and possibly persistence of the transgene for with NOS inhibitors. Hence, these data demonstrate the extended periods. potential for NO to function as an autocrine regulator of Prior to proceeding with iNOS gene therapy, Tzeng et vascular events necessary for re-endothelialization and al. [54] studied the requirements for assembly of the iNOS perhaps angiogenesis. These properties favor healing of the enzyme subunits into an active dimer. They used a injured vasculature in the sense that more rapid coverage retrovirus to transfect NIH 3T3 cells with the human iNOS of the injured site with endothelium will diminish the cDNA. NIH 3T3 cells were utilized because of their stimulus for platelet adherence and leukocyte chemotaxis, deficiency of de novo tetrahydrobiopterin (H B) biosyn- 4 and hence the stimulation of growth factors and cytokines thesis. Cells infected with iNOS that were not exposed to that continually drive vascular VSMC proliferation and exogenous H B synthesized low levels of NO compared to 4 migration. In support of this conclusion, Guo et al. [45] cells exposed to exogenous supplemental H B in the form 4 showed that administration of a NO donor in vivo accelerof either tetrahydrobiopterin or its precursor sepiapterin. ated the regrowth of the endothelium following carotid
The increased amount of NO produced in response to injury in rats. This same group found that the NO donor supplemental H B was not due to an increase in iNOS 4 dose-dependently inhibited PDGF-BB stimulated RAMSC protein. Instead, it was due an increased percentage of proliferation while it stimulated RAEC proliferation. dimeric forms of iNOS, raising from 20 to 66% in the Again, demonstrating that the effects of NO in the vessel groups receiving H B. Thus, this demonstrates that H B 4 4 wall are cell specific and aimed at promoting vessel repair. plays a critical role in the dimerization and activation of Most recently, in 1997, Tzeng et al. [46] demonstrated iNOS, revealing a post-translational mechanism by which yet another beneficial effect of NO on endothelial cells. intracellular H B can regulate iNOS expression. Further 4 Overexpression of iNOS using a adenoviral vector instudies revealed that the requirement for H B could be met 4 creased endothelial proliferation and suppressed apoptosis. by the co-transfer of the cDNA for GTP-cyclohydrolase, This work continues the study of Dimmeler et al. [47] that the rate-limiting enzyme for H B biosynthesis. Whether 4 showed that NO is a potent inhibitor of apoptosis in H B will be limiting in vivo remains to be determined. 4 endothelial cells and that the inhibition of apoptosis occurs In 1996, Tzeng et al. [55] delivered retroviral-mediated through the suppression of caspase 3-like protease activity.
human iNOS to isolated porcine arterial segments ex vivo. Vessels infected with iNOS produced more nitrite and cGMP compared to vector infected vessels. Additionally, 5. Inducible nitric oxide synthase gene transfer there was complete inhibition of the development of myointimal thickening following balloon catheter injury in 5.1. Arterial injury the ex vivo system despite the 1% transfer efficiency observed. This very low iNOS gene transfer had significant Given all of the vasoprotective properties of NO, it effects on vessel wall responses. seemed reasonable that overexpression of iNOS locally at
To demonstrate the efficacy of iNOS overexpression in the site of vascular injury would be beneficial in inhibiting the vasculature following injury, Shears et al. [52] demonthe development of intimal hyperplasia. Systemic adminisstrated that adenoviral delivery of the human iNOS gene to tration of NO donors can be associated with deleterious both rat carotid and pig iliac arteries following injury side-effects such as hypotension and may require continusignificantly inhibited the development of intimal hyperous administration. Gene therapy using iNOS is an attracplasia. First, they demonstrated that adenoviral iNOS tive approach to locally increase NO production in a (AdiNOS) infection of RASMCs produced 100-fold more sustained manner and all three NOS isoforms have been nitrite than control and AdlacZ-infected cells. AdiNOS or used with some success [48] [49] [50] [51] [52] [53] . Although many vectors AdLacZ was then transferred intralumenally to the rat may prove useful, the adenoviral vector has a relatively carotid artery following balloon-induced injury using a 6 high transfer efficiency to the vasculature compared to very low titer of 2310 pfu per artery. Evaluation of the other vectors, and the duration of expression of the carotid arteries 2 weeks following injury and infection transgene can be approximately 2 weeks. Theoretically, resulted in a 96.7% inhibition of neointimal thickening. this may be the optimal period of NO production. iNOS is
The investigators then evaluated the efficiency of iNOS capable of producing large quantities of NO in a sustained, gene transfer in a model more similar to humans, namely 8 the pig iliac artery injury model. Delivery of 5310 pfu increase in iNOS mRNA and protein [66] . Therefore, it per artery of AdiNOS or AdLacZ resulted in a 51.8% was suggested that iNOS may be playing a detrimental role reduction in the intima / media area ratio in the vessels in the pathophysiology of transplant vasculopathy. infected with AdiNOS. This study demonstrated that very More definitive studies on the role of iNOS in transplant low titers of adenovirus encoding the iNOS gene had vasculopathy were performed in the past 2 years. Shears et profound effects in two different animal models of arterial al. [67] delivered an inhibitor of iNOS, L-NIL, to rats injury. These are among the lowest titers reported to be receiving an aortic allograft systemically via an alzet effective for any gene therapy approach using adenoviral osmotic pump. They found that rats receiving L-NIL had vectors in the cardiovascular system [56] . These titers are 57% more intimal thickening at 4 weeks, indicating that well below the threshold associated with inflammation and NO suppresses the development of allograft arteriosclerothe increased intimal hyperplasia associated with adenosis. To extend these observation they performed gene virus used in some studies [57, 58] . Thus, the efficacy as transfer with an adenoviral vector carrying the human well as feasibility of iNOS gene transfer to the vasculature iNOS gene to allogeneic rat aortic transplants and evaluto prevent the arterial injury response has been successfulated the transplanted aortae for transplant vasculopathy. 7 ly demonstrated. The applicability of this approach in a Following delivery of just 2310 pfu of adenoviral iNOS clinical setting however remains to be determined. The to explanted aortae prior to transplantation they found a above studies were performed in normal arteries, therefore near complete inhibition of intimal thickening at 28 days it will be imperative to determine the efficacy of iNOS post-transplantation. This study would predict that effecgene transfer in atherosclerotic animal models, as this tive supplementation of NO would limit coronary transcellular environment may respond differently to adenoviral plant vasculopathy. gene transfer and NO overproduction.
The negative role of iNOS was confirmed by Koglin et al. [68] . They transplanted allogeneic hearts into iNOS 5.2. Transplant vasculopathy 2 / 2 and iNOS 1 / 1 mice and evaluated the coronary arteries for signs of transplant vasculopathy. Interestingly, One of the long-term limitations of cardiac transplantathe iNOS 2 / 2 recipients displayed significantly more tion is accelerated graft coronary arteriosclerosis. This neointimal thickening compared to the iNOS 1 / 1 recipidisease can be detected by coronary angiography in 6-ents. From these two studies it appears that iNOS may play 18% of cardiac recipients at 1 year and as many as 50% at a protective role in the short term development of trans-5 years [59, 60] . The hallmark manifestation of this process plant arteriosclerosis, suppressing neointimal smooth musis diffuse, progressive narrowing of the coronary arteries cle cell accumulation. due to severe intimal thickening comprised of phenotypically modulated vascular smooth muscle cells [61] . Similar to restenosis following balloon angioplasty, allog-6. Summary raft arteriosclerosis involves the proliferation and migration of SMCs from the media to the intima under the Following injury to the vasculature, the expression of influence of mitogenic signals. One theory for the etiology iNOS is upregulated with subsequent synthesis of large of this complex process is that cellular and humoral quantities of NO. This NO production has been found to immune responses initiate a cascade of cytokines and serve as a powerful vasoprotective agent by inhibiting growth factors that induce immune-mediated endothelial platelet aggregation, leukocyte chemotaxis, VSMC proliferinjury [62] . VSMCs exposed to these mitogenic stimuli ation, VSMC migration, and by promoting endothelial cell convert from a contractile to synthetic phenotype, begin to survival and growth. Many groups have demonstrated the proliferate, migrate from the media to the intima, and lead therapeutic potential of NO in preventing the arterial injury to the development of diffuse coronary artery graft neointiresponse in animal models of arterial injury. Much remains mal thickening.
to be learned about how NO regulates these processes at The role of NO and iNOS in transplant vasculopathy has the molecular level, and to determine how NO is able to been quite complex. Several groups have demonstrated an execute such diverse actions in different cell types. It increase in plasma and urine nitrite levels following seems likely that effective therapies based on NO and allogeneic cardiac transplant rejection but not in syngeneic specifically iNOS will positively impact on cardiovascular transplants [63, 64] . The increase in urinary nitrite propathology. duction was completely inhibited with L-NMMA, demonstrating that this was due to increased production of NO. iNOS expression was later found to correlate with the production of NO within the cardiac allografts during acute 
